文献库搜索 | GeneLibs

Angappan(P),Duraisamy(P),Chellamuthu(P),Ag... PLoS One None

...MoS₂ lubrication. Four tool configurations were examined: non-textured (NT), parallel-textured (PT), elliptical-textured...

Matsuda(R),Hontsu(S),Tamamoto(T),Inooka(N)... Brain Tumor Res Treat 2026-04-00

...mOS) after SRS/fSRT was 25.1 months (95% confidence interval [CI]: 18.4-33.5 months). The mOS after initial treatment fo...

Zhang(M),Zhang(X),Lin(T),Liu(B),Hao(J),Gao... Cancers (Basel) 2026-05-02

...mOS (34.3 vs. 22.0 months, p < 0.0001) and mPFS (16.7 vs. 12.7 months, p < 0.001). The ORR was significantly higher in t...

DiPippo(SM),Roth-Monzón(A),Bolnick(DI),Pad... bioRxiv 2026-02-24

...MOs) allow transient gene knockdown in adult organisms with high specificity and low toxicity. Vivo-MOs are used in cell...

Navarro-Compán(V),Kiltz(U),Mease(PJ),Dubre... RMD Open 2026-05-13

...MOS-Sleep-R) Index II) and HRQoL (36-Item Short Form Questionnaire (SF-36) Physical Component Summary (PCS)/Mental Compo...

Roque(S),Ben Choug(C),Khodja(CH),Vigneron(... Nat Commun 2026-05-13

...Mos-MAPK-Rsk1/2 pathway fails to activate due to the absence of c-Mos as a consequence of its improper degradation. Over...

Ji(Z),Wang(X),Ma(L),Xin(J),Wang(Y),Liu(S),... NPJ Precis Oncol 2026-05-13

...mOS 14.3 months; ORR 65.0%) versus later-line therapy. Median PFS was 6.8 months in the NET G3 cohort and 2.1 months in ...

Decraecker(M),Guiu(B),Boleslawski(E),Nahon... J Liver Cancer 2026-05-14

...mOS] 56 months, 95% CI [54-58]) and 88% and 80% after resection (mOS 75 months, 95% CI [72-79]). Median time to next tre...

Sun(Z),Xin(W),Tian(Y),Lu(S),Wang(Y),Li(L),... Lung Cancer 2026-07-00

...mOS) was 20.52 months. Further analysis revealed that patients receiving 4-6 cycles of chemotherapy achieved prolonged O...

Shimizu(J),Nishio(M),Ohashi(K),Osoegawa(A)... Cancer Sci 2026-07-00

...mOS/PFS vs. patients with ECOG PS ≥ 2 and G8 score